Lexicon announces positive 52-week results from sotagliflozin in tandem2 study
Lexicon announced positive 52-week results from the Phase 3 inTandem2 study for sotagliflozin in adults with type 1 diabetes. In the European study, sotagliflozin in combination with maximally tolerated standard of care insulin therapy demonstrated statistically significant reductions in A1C levels. June 23, 2018